Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06699810 · ClinicalTrials.gov registry record · Phase 4
Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity
A Phase 4 study of Ketosis Prone Diabetes, sponsored by Emory University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT06699810 is a Phase 4 study of Ketosis Prone Diabetes that is actively recruiting participants, run by Emory University. The registered enrollment target is 12 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT06699810, a Phase 4 study of Ketosis Prone Diabetes, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
The goal of this study is to quantify day-to-day changes in blood glucose during treatment towards remission in ketosis-prone diabetes (KPDM) and describe them using a mathematical model of KPDM pathogenesis and remission.
Conditions Studied
Interventions
- DRUG Insulin
- DEVICE Continuous Glucose Monitoring
Study Locations (2)
Georgia
- Grady Health System - Atlanta
- Emory University Hospital Midtown - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-01-23 |
| Est. Completion | 2025-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06699810
The ClinicalTrials.gov registry entry for NCT06699810 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ketosis Prone Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Insulin is the first listed.
NCT06699810 reports 2 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT06699810 about?
NCT06699810 is a clinical study titled "Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity". The goal of this study is to quantify day-to-day changes in blood glucose during treatment towards remission in ketosis-prone diabetes (KPDM) and describe them using a mathematical model of KPDM pathogenesis and remission.
What is the current status of trial NCT06699810?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 12 participants. The study started on 2025-01-23. Estimated completion is 2025-12.
What conditions does trial NCT06699810 study?
This clinical trial studies the following conditions: Ketosis Prone Diabetes.
What interventions are being tested in trial NCT06699810?
The interventions under investigation include: Insulin (DRUG), Continuous Glucose Monitoring (DEVICE).
Who is sponsoring clinical trial NCT06699810?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06699810 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ketosis Prone Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.